| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0166-2236(90)90111-M |
| P698 | PubMed publication ID | 1695405 |
| P2093 | author name string | DiFiglia M | |
| P433 | issue | 7 | |
| P921 | main subject | Huntington's disease | Q190564 |
| excitotoxicity | Q901117 | ||
| P304 | page(s) | 286-289 | |
| P577 | publication date | 1990-07-01 | |
| P1433 | published in | Trends in Neurosciences | Q3538443 |
| P1476 | title | Excitotoxic injury of the neostriatum: a model for Huntington's disease | |
| P478 | volume | 13 |
| Q50974457 | 1-Benzyl-1,2,3,4-tetrahydro-β-carboline as channel blocker of N-methyl-D-aspartate receptors. |
| Q48637738 | 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces [3H]AMPA binding in rat striatum |
| Q48613623 | A developmental expression of AMPA-selective glutamate receptor subunits in human basal ganglia |
| Q40763937 | A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands |
| Q36719669 | A systematic review of the treatment studies in Huntington's disease since 1990. |
| Q45291024 | Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input |
| Q45929789 | Acute intrastriatal administration of quinolinic acid affects the expression of the coat protein AP-2 and its interaction with membranes. |
| Q44506386 | Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease. |
| Q36083482 | Adenosine and brain function |
| Q45298550 | Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease |
| Q36984277 | Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. |
| Q24657764 | Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease |
| Q48167280 | Alteration of free radical metabolism in the brain of mice infected with scrapie agent |
| Q92876042 | Alterations of Calcium Channels in a Mouse Model of Huntington's Disease and Neuroprotection by Blockage of CaV1 Channels |
| Q40149501 | Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. |
| Q37432151 | Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene |
| Q45299599 | Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease |
| Q37002862 | Altered information processing in the prefrontal cortex of Huntington's disease mouse models |
| Q33703899 | Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease |
| Q41741254 | Apoptosis, neurotrophic factors and neurodegeneration |
| Q44413269 | Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6‐OHDA hemilesioned rat |
| Q40469094 | Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum. |
| Q48172704 | Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo |
| Q40826187 | Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease |
| Q40020558 | Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells |
| Q44495460 | Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. |
| Q41911647 | Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model |
| Q34053585 | Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease |
| Q33734410 | Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease |
| Q45293741 | Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum |
| Q42528675 | Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. |
| Q101403055 | Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease |
| Q28589793 | Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease |
| Q45301002 | Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease |
| Q42480737 | Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. |
| Q37503857 | Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease |
| Q48463301 | Co-administration of adenosine kinase and deaminase inhibitors produces supra-additive potentiation of N-methyl-D-aspartate-evoked adenosine formation in cortex |
| Q37160164 | Compartmentalization of excitatory amino acid receptors in human striatum |
| Q89963713 | Cortical and Striatal Circuits in Huntington's Disease |
| Q26738379 | Corticostriatal Dysfunction in Huntington's Disease: The Basics |
| Q34520437 | Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease |
| Q48320992 | Differential alterations in basal and D-amphetamine-induced behavioural pattern following 6-OHDA or ibotenic acid lesions into the dorsal striatum |
| Q40102175 | Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease |
| Q48147783 | Differential expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits by calretinin-immunoreactive neurons in the human striatum |
| Q37073493 | Differential expression of neurotrophins in postnatal C57BL/6 mice striatum |
| Q36012795 | Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats |
| Q43892553 | Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. |
| Q52690256 | Disrupted striatal neuron inputs and outputs in Huntington's disease. |
| Q44918606 | Distinct expression of phosphorylated N-methyl-D-aspartate receptor NR1 subunits by projection neurons and interneurons in the striatum of normal and amphetamine-treated rats |
| Q38121068 | Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility |
| Q48345597 | Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons |
| Q41185198 | Dyskinesias and their treatment with essential fatty acids: a review |
| Q39041217 | Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation |
| Q34293784 | Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice |
| Q73306307 | Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid |
| Q42965014 | Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions |
| Q45295777 | Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease |
| Q44968954 | Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease |
| Q45301294 | Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene |
| Q45289028 | Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy |
| Q48523372 | Examination of parameters influencing [3H]MK-801 binding in postmortem human cortex |
| Q86652079 | Excitatory amino acidergic pathways and receptors in the basal ganglia |
| Q40852160 | Excitotoxicity and alcohol-related brain damage |
| Q31813509 | Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. |
| Q48401039 | Expression of interleukin 6 in the rat striatum following stereotaxic injection of quinolinic acid |
| Q28508248 | Expression of normal and mutant huntingtin in the developing brain |
| Q35161675 | Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. |
| Q40949615 | Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. |
| Q40859661 | From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease |
| Q36861129 | Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. |
| Q37731940 | Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q41087697 | Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease |
| Q36016647 | Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease |
| Q39178944 | Glutamate transporter expression and function in a striatal neuronal model of Huntington's disease |
| Q35585297 | HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity |
| Q48635231 | Histamine modulates NMDA-dependent swelling in the neostriatum. |
| Q33614725 | Human nerual stem cells for brain repair |
| Q48119453 | Human striatum: Chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease |
| Q28281434 | Huntingtin and its role in neuronal degeneration |
| Q24317574 | Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons |
| Q24601142 | Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase |
| Q37820343 | Huntington's disease and Group I metabotropic glutamate receptors |
| Q37996350 | Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease |
| Q64983156 | Huntington's disease: From basic science to therapeutics. |
| Q37723234 | Huntington's disease: pathogenesis to animal models. |
| Q33921449 | Huntington's disease: pathogenesis, diagnosis and treatment |
| Q57178431 | Huntington's disease: the coming of age |
| Q43867859 | Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice |
| Q33999262 | Immunohistochemical localization of AMPA-type glutamate receptor subunits in the striatum of rhesus monkey |
| Q44548881 | In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. |
| Q28343012 | Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission |
| Q43925468 | Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease |
| Q34152284 | Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease |
| Q64968129 | Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review |
| Q39804344 | Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. |
| Q48284526 | Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo |
| Q34320159 | Ion channel diseases of the central nervous system. |
| Q31916191 | Isoform-specific translocation of protein kinase C following glutamate administration in primary hippocampal neurons |
| Q29398467 | Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies |
| Q34377561 | L-Type Ca(2+) channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons |
| Q43759861 | Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease |
| Q38347060 | Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's disease |
| Q37200818 | Localization of the protein kinase C phosphorylation/calmodulin-binding substrate RC3 in dendritic spines of neostriatal neurons |
| Q34560517 | Mechanisms of disease: Histone modifications in Huntington's disease |
| Q33834203 | Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism |
| Q48810698 | Mesencephalic neuron death induced by congeners of nitrogen monoxide is prevented by the lazaroid U-83836E. |
| Q38239515 | Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease |
| Q43120924 | Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease |
| Q42465415 | Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q34383634 | Molecular components of striatal plasticity: the various routes of cyclic AMP pathways |
| Q48141290 | Morphology and compartmental location of cells exhibiting DNA damage after quinolinic acid injections into rat striatum |
| Q34502714 | Mouse models of Huntington's disease |
| Q36686156 | Multiple pathways contribute to the pathogenesis of Huntington disease |
| Q43601269 | Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways |
| Q37308357 | Mutant huntingtin and mitochondrial dysfunction |
| Q30145688 | N-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by Zika Virus Infection |
| Q41153232 | N-methyl-d-aspartate receptor activation in the neostriatum increases c-fos and fos-related antigens selectively in medium-sized neurons |
| Q38079295 | Neural stem cell-based treatment for neurodegenerative diseases |
| Q73389341 | Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1 |
| Q34657624 | Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. |
| Q40777710 | Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members |
| Q26995351 | Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease |
| Q44395839 | Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage |
| Q45301079 | Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. |
| Q34426624 | Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease |
| Q40873179 | Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease |
| Q35243890 | New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease |
| Q55690358 | Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt. |
| Q37460122 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease |
| Q26775096 | Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders |
| Q71889758 | Organotypic slice cultures of the rat striatum: an immunocytochemical, histochemical and in situ hybridization study of somatostatin, neuropeptide Y, nicotinamide adenine dinucleotide phosphate-diaphorase, and enkephalin |
| Q90439419 | Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences |
| Q37930190 | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. |
| Q28661435 | Plants and phytochemicals for Huntington's disease |
| Q50325917 | Polyamines: Bio-Molecules with Diverse Functions in Plant and Human Health and Disease |
| Q36142706 | Potential drugs and methods for preventing or delaying the progression of Huntington's disease |
| Q73405627 | Presence of NMDA-type glutamate receptors in cingulate corticostriatal terminals and their postsynaptic targets |
| Q41108601 | Programming of single movements in Parkinson's disease: comparison with Huntington's disease. |
| Q36346512 | Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine |
| Q41180628 | Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells |
| Q46923350 | Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors |
| Q37540988 | Protein aggregates in Huntington's disease. |
| Q44828223 | Quinolinic acid lesions of the caudate putamen in the rat lead to a local increase of ciliary neurotrophic factor. |
| Q72140321 | Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury |
| Q24292161 | Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi |
| Q37734247 | Regulation of N-methyl-D-aspartate-induced toxicity in the neostriatum: a role for metabotropic glutamate receptors? |
| Q34074824 | Remacemide: current status and clinical applications |
| Q42513393 | Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene |
| Q33606063 | Seeking brain biomarkers for preventive therapy in Huntington disease. |
| Q36597920 | Selective neuronal degeneration in Huntington's disease |
| Q30955390 | Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond |
| Q33614689 | Stem Cells Transplantation and Huntington's Disease |
| Q37028233 | Stem cell-based cell therapy for Huntington disease: a review |
| Q33831774 | Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity |
| Q45206241 | Striatal potassium channel dysfunction in Huntington's disease transgenic mice |
| Q34120774 | Striatal tissue transplantation in non-human primates |
| Q40744948 | Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease |
| Q40958511 | Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin |
| Q40956724 | Synaptic transmission and modulation in the neostriatum |
| Q45943807 | Systemic transplantation of mesenchymal stem cells can reduce cognitive and motor deficits in rats with unilateral lesions of the neostriatum. |
| Q48859471 | Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures |
| Q34380089 | The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons |
| Q35597607 | The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review |
| Q37921617 | The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition |
| Q73138936 | The connections of the primate subthalamic nucleus: indirect pathways and the open-interconnected scheme of basal ganglia-thalamocortical circuitry |
| Q36684263 | The corticostriatal pathway in Huntington's disease |
| Q45289824 | The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. |
| Q45298619 | The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease |
| Q24676589 | The localization and interactions of huntingtin |
| Q48188055 | The neurotrophin receptors trkA, trkB and trkC are differentially regulated after excitotoxic lesion in rat striatum. |
| Q36045254 | The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration |
| Q36833070 | The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses |
| Q33639170 | The role of excitotoxicity in neurodegenerative disease: implications for therapy |
| Q50420577 | Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings. |
| Q36999830 | Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body |
| Q28587110 | Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats |
| Q36752799 | Transcriptional signatures in Huntington's disease |
| Q35563080 | Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity |
| Q44306949 | Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. |
| Q34160408 | Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice |
| Q36466901 | Where do you think you are going? The NMDA-D1 receptor trap |
| Q33772241 | White matter loss in a mouse model of periventricular leukomalacia is rescued by trophic factors |
| Q42503942 | Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues |
| Q56796063 | mGluR5: a potential target for the treatment of Huntington's disease |
Search more.